Obesity & Overweight

Metabolic Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
CagrilintidePhase 1Peptide1 trial
Active Trials
NCT04940078Completed40Est. Feb 2022
Closed Loop Medicine
Closed Loop MedicineUK - Cambridge
1 program
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. AdultsN/APeptide1 trial
Active Trials
NCT07216651RecruitingEst. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskCagrilintide
Closed Loop MedicineWeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Clinical Trials (2)

Total enrollment: 40 patients across 2 trials

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Start: Jul 2021Est. completion: Feb 202240 patients
Phase 1Completed
NCT07216651Closed Loop MedicineWeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

Start: Sep 2025Est. completion: Jan 2026
N/ARecruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 40 patients
2 companies competing in this space